CY1126097T1 - Αγωνιστες του υποδοχεα glp-1 και χρησεις αυτων - Google Patents

Αγωνιστες του υποδοχεα glp-1 και χρησεις αυτων

Info

Publication number
CY1126097T1
CY1126097T1 CY20231100347T CY231100347T CY1126097T1 CY 1126097 T1 CY1126097 T1 CY 1126097T1 CY 20231100347 T CY20231100347 T CY 20231100347T CY 231100347 T CY231100347 T CY 231100347T CY 1126097 T1 CY1126097 T1 CY 1126097T1
Authority
CY
Cyprus
Prior art keywords
glp
receptor agents
aza
benzimidazoles
compounds
Prior art date
Application number
CY20231100347T
Other languages
English (en)
Inventor
Gary Erik Aspnes
Scott W. Bagley
John M. Curto
David James EDMONDS
Mark E. Flanagan
Kentaro Futatsugi
David A. Griffith
Kim HUARD
Yajing Lian
Chris Limberakis
Allyn T. Londregan
Alan M. Mathiowetz
David W. Piotrowski
Roger B. Ruggeri
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of CY1126097T1 publication Critical patent/CY1126097T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/02—Formic acid
    • C07C53/06—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Εδώ παρέχονται 6-καρβοξυλικά οξέα βενζιμιδαζολίων και 4-αζα- 5-αζα-, και 7-αζα-βενζιμιδαζολίων ως αγωνιστές του GLP-1 R, διεργασίες για την παρασκευή των ρηθέντων ενώσεων, και μέθοδοι που περιλαμβάνουν τη χορήγηση των ρηθέντων ενώσεων σε ένα θηλαστικό που χρήζει αυτών (Τύπος Ι).
CY20231100347T 2018-06-13 2023-07-19 Αγωνιστες του υποδοχεα glp-1 και χρησεις αυτων CY1126097T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862684696P 2018-06-13 2018-06-13
US201962846944P 2019-05-13 2019-05-13
US201962851206P 2019-05-22 2019-05-22
PCT/IB2019/054867 WO2019239319A1 (en) 2018-06-13 2019-06-11 Glp-1 receptor agonists and uses thereof

Publications (1)

Publication Number Publication Date
CY1126097T1 true CY1126097T1 (el) 2023-11-15

Family

ID=67003576

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20231100347T CY1126097T1 (el) 2018-06-13 2023-07-19 Αγωνιστες του υποδοχεα glp-1 και χρησεις αυτων

Country Status (38)

Country Link
US (5) US10934279B2 (el)
EP (2) EP3806955B9 (el)
JP (1) JP6916968B1 (el)
KR (1) KR102542199B1 (el)
CN (1) CN112533674A (el)
AU (1) AU2019285491B2 (el)
BR (1) BR112020024470A2 (el)
CA (1) CA3045644C (el)
CL (1) CL2020003222A1 (el)
CO (1) CO2020015305A2 (el)
CR (1) CR20200612A (el)
CU (1) CU20200099A7 (el)
CY (1) CY1126097T1 (el)
DK (1) DK3806955T3 (el)
EC (1) ECSP20078651A (el)
ES (1) ES2949954T3 (el)
FI (1) FI3806955T3 (el)
GE (1) GEP20237453B (el)
HR (1) HRP20230631T1 (el)
HU (1) HUE063074T2 (el)
IL (1) IL279300B2 (el)
LT (1) LT3806955T (el)
MD (1) MD3806955T3 (el)
MX (1) MX2020013625A (el)
NI (1) NI202000091A (el)
NZ (1) NZ770240A (el)
PE (2) PE20211601A1 (el)
PH (1) PH12020552069A1 (el)
PL (1) PL3806955T3 (el)
PT (1) PT3806955T (el)
RS (1) RS64323B9 (el)
SG (1) SG11202011465QA (el)
SI (1) SI3806955T1 (el)
TW (1) TWI707683B (el)
UA (1) UA124371C2 (el)
UY (1) UY38261A (el)
WO (1) WO2019239319A1 (el)
ZA (1) ZA202007572B (el)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3045644C (en) * 2018-06-13 2024-01-16 Pfizer Inc. Glp-1 receptor agonists and uses thereof
AU2019285570B2 (en) 2018-06-15 2022-03-24 Pfizer Inc. GLP-1 receptor agonists and uses thereof
JP2022508203A (ja) * 2018-11-22 2022-01-19 キル・レガー・セラピューティクス・インコーポレーテッド Ｇｌｐ－１ｒアゴニスト及びその使用
US10954221B2 (en) 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
US20220387402A1 (en) * 2019-05-20 2022-12-08 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
TWI751585B (zh) 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
CR20220178A (es) 2019-10-25 2022-06-15 Gilead Sciences Inc Compuestos moduladores de glp-1r
WO2021116874A1 (en) * 2019-12-10 2021-06-17 Pfizer Inc. Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
US20220288030A1 (en) * 2020-01-29 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
KR20220156535A (ko) 2020-02-07 2022-11-25 가셔브룸 바이오, 인크. 헤테로사이클릭 glp-1 작용제
CN113493447B (zh) * 2020-04-03 2024-06-11 轩竹(北京)医药科技有限公司 Glp-1受体激动剂
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
TW202206429A (zh) * 2020-04-29 2022-02-16 美商迦舒布魯姆生物有限公司 雜環ｇｌｐ—１促效劑
US20230234968A1 (en) * 2020-06-10 2023-07-27 Medshine Discovery Inc. Methyl-substituted benzobisoxazole compound and use thereof
WO2021254470A1 (zh) * 2020-06-19 2021-12-23 江苏恒瑞医药股份有限公司 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
CN113816948B (zh) * 2020-06-19 2023-08-11 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
MX2023001311A (es) 2020-08-06 2023-04-18 Gasherbrum Bio Inc Agonistas heterociclicos de glp-1.
TW202214622A (zh) * 2020-08-06 2022-04-16 大陸商上海齊魯銳格醫藥研發有限公司 Ｇｌｐ－１ｒ促效劑及其用途
EP4204415A1 (en) 2020-08-28 2023-07-05 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN115884969A (zh) * 2020-09-01 2023-03-31 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CN115515956B (zh) * 2020-09-29 2024-06-25 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
EP4229050A1 (en) * 2020-10-13 2023-08-23 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN114478694A (zh) * 2020-11-13 2022-05-13 成都奥达生物科技有限公司 一种长效mc4r激动剂
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
CA3200245A1 (en) 2020-11-27 2022-06-02 Junjun Wu Benzimidazole derivative and preparation method therefor and medical use thereof
CN114591308B (zh) 2020-12-03 2024-03-08 苏州闻泰医药科技有限公司 一类glp-1r受体激动剂化合物及其用途
JP2024505250A (ja) * 2021-01-28 2024-02-05 カーモット セラピューティクス インコーポレイテッド Ｇｐｃｒ受容体アゴニスト、それを含む医薬組成物、及びそれらの使用方法
WO2022184849A1 (en) 2021-03-04 2022-09-09 Les Laboratoires Servier Glp-1r agonists, uses and pharmaceutical compositions thereof
JPWO2022202864A1 (el) 2021-03-24 2022-09-29
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
US11858918B2 (en) 2021-04-21 2024-01-02 Gilead Sciences, Inc. GLP-1R modulating compounds
CN117177970A (zh) * 2021-04-30 2023-12-05 上海翰森生物医药科技有限公司 多环类衍生物调节剂、其制备方法和应用
AU2022271223A1 (en) * 2021-05-03 2023-11-02 Carmot Therapeutics, Inc. Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
AU2022275931A1 (en) 2021-05-20 2023-11-02 Eli Lilly And Company Macrocyclic glucagon-like peptide 1 receptor agonists
CN117715906A (zh) * 2021-07-21 2024-03-15 和博医药有限公司 胰高血糖素样肽-1受体调节剂及其用途
CN113480534B (zh) * 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用
IL310400A (en) * 2021-08-04 2024-03-01 Shanghai Hansoh Biomedical Co Ltd Modulating cycloalkyne derivative preparation method for this, as well as this application
EP4393914A1 (en) * 2021-08-24 2024-07-03 Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. Imidazocyclic compound and application thereof
JPWO2023038039A1 (el) 2021-09-08 2023-03-16
WO2023057429A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
KR20240073108A (ko) * 2021-10-05 2024-05-24 아스트라제네카 아베 Glp-1 수용체 조절제로서의 특정 2,5-디아자바이시클로[4.2.0]옥탄
WO2023057414A1 (en) * 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
CN115991685A (zh) 2021-10-20 2023-04-21 韶远科技（上海)有限公司 一种氧杂环丁烷-2-甲胺的制备方法
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
WO2023106310A1 (ja) * 2021-12-07 2023-06-15 塩野義製薬株式会社 Ｇｌｐ－１受容体アゴニスト活性を有する芳香族複素環誘導体
CN113974618B (zh) * 2021-12-12 2022-09-13 广西澍源智能科技有限公司 基于水峰血糖修正的无创血糖测试方法
WO2023111145A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023111144A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
TW202328114A (zh) * 2021-12-23 2023-07-16 大陸商江蘇恒瑞醫藥股份有限公司 Glp-1受體激動劑的可藥用鹽、結晶形式及其製備方法
AU2022422997A1 (en) * 2021-12-23 2024-07-11 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystalline form of glp-1 receptor agonist and preparation method therefor
CN116354945A (zh) * 2021-12-27 2023-06-30 长春金赛药业有限责任公司 一种稠合咪唑羧酸类化合物及其制备方法和应用
WO2023151574A1 (en) * 2022-02-09 2023-08-17 Gasherbrum Bio Inc. Heterocyclic glp-1 agonists
WO2023151575A1 (en) * 2022-02-09 2023-08-17 Gasherbrum Bio Inc. Heterocyclic glp-1 agonists
WO2023152698A1 (en) 2022-02-10 2023-08-17 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
WO2023164358A1 (en) * 2022-02-28 2023-08-31 Ascletis Bioscience Co., Ltd. Glp-1r modulating compounds
WO2023169436A1 (zh) * 2022-03-08 2023-09-14 广州市联瑞制药有限公司 苯并双环类化合物及其制备方法和应用
WO2023228023A1 (en) * 2022-05-23 2023-11-30 Pfizer Inc. Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof
WO2024051749A1 (zh) * 2022-09-06 2024-03-14 德睿智药(苏州)新药研发有限公司 一种glp-1r激动剂化合物的多晶型物及其制备方法与用途
WO2024063143A1 (ja) * 2022-09-22 2024-03-28 塩野義製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を有する縮合環化合物
WO2024102625A1 (en) 2022-11-11 2024-05-16 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
WO2024107781A1 (en) 2022-11-16 2024-05-23 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
USD1011080S1 (en) 2023-07-28 2024-01-16 Voilasophy, Llc. Yoga storage rack

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1994021615A1 (en) 1993-03-18 1994-09-29 Merck Sharp & Dohme Limited Benzimidazole derivatives
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
EP1235572A2 (en) 1999-10-29 2002-09-04 MERCK SHARP & DOHME LTD. Method to treat pain utilizing benzimidazole nmda/nr2b antagonists
EP1351936A1 (en) 2001-01-15 2003-10-15 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
WO2003060475A2 (en) * 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues
US20040127504A1 (en) 2002-09-06 2004-07-01 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
MY140489A (en) 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
WO2008012623A1 (en) 2006-07-25 2008-01-31 Pfizer Products Inc. Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
WO2010114824A1 (en) 2009-03-30 2010-10-07 Transtech Pharma Inc Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
CH702192A1 (de) 2009-11-04 2011-05-13 New Dent Ag Keramisches Implantat.
WO2011097491A1 (en) * 2010-02-04 2011-08-11 Glaxosmithkline Llc Benzimidazole antiviral agents
JP5702855B2 (ja) 2010-05-13 2015-04-15 アムジエン・インコーポレーテツド Ｐｄｅ１０阻害剤として有用な窒素複素環化合物
ES2602111T3 (es) 2010-09-30 2017-02-17 Pfizer Inc Inhibidores de acetil-CoA carboxilasas de N1-pirazoloespirocetona
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
US20150376198A1 (en) 2013-02-18 2015-12-31 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
WO2016029146A1 (en) 2014-08-22 2016-02-25 University Of Washington Specific inhibitors of methionyl-trna synthetase
CA3001857A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
MX2018007755A (es) 2015-12-29 2018-11-09 Pfizer 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa.
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
CN106271089B (zh) 2016-09-30 2019-01-25 英诺激光科技股份有限公司 一种激光薄膜刻蚀装置及方法
CA3045644C (en) * 2018-06-13 2024-01-16 Pfizer Inc. Glp-1 receptor agonists and uses thereof
US20220387402A1 (en) * 2019-05-20 2022-12-08 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases

Also Published As

Publication number Publication date
EP3806955B1 (en) 2023-05-31
RS64323B9 (en) 2023-11-30
DK3806955T3 (da) 2023-06-26
US20190382387A1 (en) 2019-12-19
MD3806955T2 (ro) 2023-09-30
US20210163455A1 (en) 2021-06-03
ES2949954T9 (es) 2023-11-23
RU2769715C1 (ru) 2022-04-05
US20190382384A1 (en) 2019-12-19
CA3045644C (en) 2024-01-16
MD3806955T3 (ro) 2024-01-31
WO2019239319A1 (en) 2019-12-19
SI3806955T1 (sl) 2023-08-31
US10934279B2 (en) 2021-03-02
CN112533674A (zh) 2021-03-19
AU2019285491B2 (en) 2021-11-11
CR20200612A (es) 2021-01-20
TWI707683B (zh) 2020-10-21
PT3806955T (pt) 2023-07-20
CU20200099A7 (es) 2021-08-06
US20240059679A1 (en) 2024-02-22
FI3806955T3 (fi) 2023-07-27
KR20210019529A (ko) 2021-02-22
KR102542199B1 (ko) 2023-06-13
US10676465B2 (en) 2020-06-09
CA3045644A1 (en) 2019-12-13
AU2019285491A1 (en) 2020-12-17
MX2020013625A (es) 2022-01-04
UY38261A (es) 2020-01-31
PE20211601A1 (es) 2021-08-18
GEP20237453B (en) 2023-01-10
IL279300A (en) 2021-01-31
EP3806955A1 (en) 2021-04-21
BR112020024470A2 (pt) 2021-03-02
US20190382388A1 (en) 2019-12-19
EP4219487A1 (en) 2023-08-02
LT3806955T (lt) 2023-07-10
NI202000091A (es) 2021-03-23
JP6916968B1 (ja) 2021-08-11
PE20240584A1 (es) 2024-03-21
NZ770240A (en) 2023-07-28
UA124371C2 (uk) 2021-09-01
CL2020003222A1 (es) 2021-04-30
PH12020552069A1 (en) 2021-05-31
ZA202007572B (en) 2023-10-25
JP2021521265A (ja) 2021-08-26
HUE063074T2 (hu) 2023-12-28
RS64323B1 (sr) 2023-08-31
IL279300B2 (en) 2023-11-01
IL279300B1 (en) 2023-07-01
TW202015679A (zh) 2020-05-01
HRP20230631T1 (hr) 2023-09-29
ES2949954T3 (es) 2023-10-04
SG11202011465QA (en) 2020-12-30
EP3806955B9 (en) 2023-08-23
ECSP20078651A (es) 2021-01-29
PL3806955T3 (pl) 2023-09-04
CO2020015305A2 (es) 2021-03-08
US10683281B2 (en) 2020-06-16

Similar Documents

Publication Publication Date Title
CY1126097T1 (el) Αγωνιστες του υποδοχεα glp-1 και χρησεις αυτων
CY1125716T1 (el) Αγωνιστες υποδοχεα glp-1 και χρησεις αυτων
MX2020013624A (es) Agonistas del receptor glp-1 y usos de los mismos.
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
CO2020003478A2 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CL2019000902A1 (es) Compuestos de benzo[b]tiofeno como agonistas de sting.
CY1125359T1 (el) Νεα υποκατεστημενα με 6-6 δικυκλικο αρωματικο δακτυλιο νουκλεοσιδικα αναλογα για χρηση ως αναστολεις prmt5
CY1124682T1 (el) Ανταγωνιστες toy trpv4
CL2017003163A1 (es) Nuevos derivados aminoácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
CO2017012991A2 (es) Agonistas de triazol del receptor apj
UY37997A (es) Agentes antivirales contra la hepatitis b
GT201300236A (es) Derivados de pirrolo (2,3-d) pirimidina como inhibidores de quinasa relacionados con tropomiosina
UY37098A (es) Moduladores de ror-gamma
ECSP16089579A (es) Proteínas agonistas de los receptores de trail de cadena simple.
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CL2017000640A1 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
AR105592A1 (es) b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS
UY38383A (es) Heterociclos funcionalizados como agentes antivirales
CR20170314A (es) Formulación de relación fija de insulina glargina/lixisenatida
AR113958A1 (es) Macrociclos a como inhibidores de pde1
AR094921A1 (es) Derivados de 2-acilaminotiazol o su sal
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
CO2018004573A2 (es) Derivados de fenilo como agonistas del receptor 2 de cannabinoides
CO2022010305A2 (es) Método y aplicación de preparación de compuesto como agente de degradación de proteínas